2025-07-24
The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

2025-07-16
Yichang Renfu Pharmaceutical's midazolam injection has been approved in France

2025-06-19
Facing the future, a two-way rush to promote the better and faster development of the pharmaceutical and health industry | Stone Dai, General Manager of China Merchants Group, investigates Renfu Pharmaceutical Group

Yichang Humanwell Pharmaceutical's Class 1 new drug RFUS-949 tablets approved for clinical trials
06
2025/06
12
2025/05
21
2025/04
01
2025/04
Yichang Renfu Pharmaceutical's Lumiracoxib Capsules (Toluene Sulfonate) Approved for Clinical Trials
31
2025/03
Yichang Renfu Pharmaceuticals Approved to Market Micafungin Sodium for Injection
17
2024/06
Yichang Renfu Ranked Top 8 in China's Brand Value Pharmaceutical and Healthcare Group
17
2024/06
Yichang Renfo Pharmaceuticals Remifentanil Approved in India
14
2024/06
ABOUT US
CONTACT
Add:66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China.
Tel:+86-717-4065884 +86-717-4065888
E-mail:yctr@renfu.com.cn
Copyright © 2024 YICHANG TIANRUI BIOPHARM CO., LTD All Rights Reserved.